S151: HIGH-THROUGHPUT EVALUATION OF THE POTENTIAL OF CANCER DRUGS TO ENHANCE NATURAL KILLER CELL IMMUNOTHERAPY IN CHRONIC MYELOID LEUKEMIA.

• P. Nygren,
• J. Bouhlal,
• E. Laajala,
• A. Ianevski,
• J. Klievink,
• H. Lähteenmäki,
• K. Saeed,
• D. Lee,
• T. Aittokallio,
• O. Dufva,
• S. Mustjoki

Affiliations

P. Nygren

1 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital

J. Bouhlal

1 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital

E. Laajala

1 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital

A. Ianevski

3 Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki, Finland

J. Klievink

1 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital

H. Lähteenmäki

1 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital

K. Saeed

1 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital

D. Lee

4 Division of Hematology, Oncology, and BMT, Nationwide Children’s Hospital, Columbus, United States of America

T. Aittokallio

3 Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki, Finland

O. Dufva

1 Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital

S. Mustjoki

2 Translational Immunology Research Program